Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

ValiRx (VAL) Share Price

Price 0.195p on 21-05-2026 at 16:30:01
Change 0.005p 2.63%
Buy 0.20p
Sell 0.19p
Last Trade: Buy 300,000.00 at 0.19649p
Day's Volume: 82,364,523
Last Close: 0.195p
Open: 0.19p
ISIN: GB00BLH13C52
Day's Range 0.195p - 0.20p
52wk Range: 0.19p - 0.80p
Market Capitalisation: £1.45m
VWAP: 0.196931p
Shares in Issue: 742.80m

ValiRx (VAL) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 300,000 0.19649p Ordinary
15:37:39 - 21-May-26
Sell* 250,000 0.19p Ordinary
15:27:10 - 21-May-26
Buy* 700 0.20p Ordinary
15:14:20 - 21-May-26
Sell* 2,100,000 0.195p Ordinary
14:56:27 - 21-May-26
Buy* 76,219 0.1968p Ordinary
14:38:14 - 21-May-26
Buy* 100,000 0.1968p Ordinary
13:49:04 - 21-May-26
Sell* 15,000 0.195p Ordinary
12:02:33 - 21-May-26
Buy* 511,137 0.197p Ordinary
11:35:51 - 21-May-26
Buy* 6,779 0.20p Ordinary
11:14:42 - 21-May-26
Buy* 220,000 0.197p Ordinary
11:01:22 - 21-May-26
See more ValiRx trades

ValiRx (VAL) Share Price History

Time period:
to
Date Open High Low Close Volume
21st May 2026 (Thu) 0.19 0.20 0.195 0.195 82,364,523
20th May 2026 (Wed) 0.19 0.19 0.19 0.19 2,190,734
19th May 2026 (Tue) 0.195 0.195 0.19 0.19 7,983,312
18th May 2026 (Mon) 0.20 0.205 0.195 0.195 7,251,415
15th May 2026 (Fri) 0.215 0.215 0.20 0.20 51,898,825
14th May 2026 (Thu) 0.27 0.241 0.241 0.241 22,845,447
13th May 2026 (Wed) 0.28 0.28 0.27 0.27 4,788,559
12th May 2026 (Tue) 0.28 0.28 0.28 0.28 2,128,266
11th May 2026 (Mon) 0.265 0.265 0.265 0.265 13,367,733
8th May 2026 (Fri) 0.265 0.265 0.265 0.265 1,510,080
7th May 2026 (Thu) 0.265 0.265 0.25 0.265 934,129
6th May 2026 (Wed) 0.265 0.265 0.265 0.265 2,202,256
5th May 2026 (Tue) 0.28 0.28 0.26 0.265 6,503,414
4th May 2026 (Mon) 0.28 0.28 0.28 0.28 0
1st May 2026 (Fri) 0.28 0.28 0.28 0.28 1,092,758
30th Apr 2026 (Thu) 0.28 0.28 0.28 0.28 13,122
29th Apr 2026 (Wed) 0.28 0.28 0.28 0.28 448,306
28th Apr 2026 (Tue) 0.28 0.28 0.28 0.28 7,638
27th Apr 2026 (Mon) 0.28 0.28 0.28 0.28 567,980
24th Apr 2026 (Fri) 0.28 0.28 0.28 0.28 447,272
23rd Apr 2026 (Thu) 0.28 0.28 0.28 0.28 1,783,894
22nd Apr 2026 (Wed) 0.28 0.28 0.28 0.28 1,662,867
See more ValiRx price history

ValiRx (VAL) Regulatory News

Date Source Headline
21st May 2026 7:00 am RNS Result of Oversubscribed WRAP Retail Offer
18th May 2026 7:00 am RNS WRAP Retail Offer for up to £150,000
15th May 2026 7:00 am RNS Fundraising of up to £1,155,000
31st Mar 2026 10:15 am RNS Change of Registered Office
26th Mar 2026 7:00 am RNS ValiRx Commercial Update Q1 2026
24th Mar 2026 7:00 am RNS ValiRx and TwinEdge to present Digital Twin data
4th Mar 2026 7:00 am RNS Director/PDMR Shareholding
2nd Mar 2026 7:00 am RNS ValiRx forms ValiRx Animal Health Ltd subsidiary
19th Jan 2026 7:00 am RNS Exercise of Warrants
9th Jan 2026 3:45 pm RNS Replacement: Evaluation and Transfer Agreement
See more ValiRx regulatory news

ValiRx (VAL) Share News

TRADING UPDATES: IAG launches new buyback; Forgent settles legal case

15th May 2026 18:23

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

WINNERS & LOSERS: Kendrick drilling results; Blackbird new approach

15th May 2026 11:49

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday. Read More

WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down

14th May 2026 10:58

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday. Read More

IN BRIEF: ValiRx establishes veterinary oncology-focused subsidiary

3rd Mar 2026 04:05

ValiRx PLC - London-based life science company - Establishes wholly owned subsidiary ValiRx Animal Health Ltd to develop and commercialise its oncology assets in the veterinary market. The subsidiary will use preclinical work from ValiRx human programmes to pursue comparative oncology opportunities. "There is a strong scientific rationale, as well as market opportunities, for this ethical approach and several examples of companies that have followed this route," says Chief Executive Officer Mark Eccleston, who adds that the three key areas of focus will be Osteosarcoma, Lymphoma and Hemangiosarcoma. ValiRx said specialist veterinary venture capitalist funds have been identified and approached with the intention that the subsidiary will be independently funded. The global veterinary oncology market was valued at USD1.58 billion in 2024 and is projected to reach USD4.86 billion by 2034, representing a compound annual growth rate of 12%. Read More

TRADING UPDATES: Life Science REIT portfolio valuation declines 7.8%

9th Jan 2026 19:14

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

See more ValiRx news
FTSE 100 Latest
Value10,443.47
Change11.13

Login to your account

Forgot Password?

Not Registered